Q2 YTD/FY2024 FINANCIAL RESULTS

from the beginning

Q2 YTD/FY2024 FINANCIAL RESULTS

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

I. Q2 YTD/FY2024 Consolidated Financial Results　FY2024 Revised Forecast

• Q2 YTD/FY2024 FINANCIAL RESULTS: OVERVIEW

• Q2 YTD/FY2024 FINANCIAL RESULTS

• Q2 YTD/FY2024 FINANCIAL RESULTS: XTANDI AND STRATEGIC BRANDS

• PADCEV: BUSINESS UPDATE

• IZERVAY: BUSINESS UPDATE (US)

• Q2 YTD/FY2024 FINANCIAL RESULTS: SG&A AND R&D EXPENSES

• FY2024 REVISED FORECAST

II. Initiatives for Sustainable Growth

• INITIATIVES FOR SUSTAINABLE GROWTH:OVERVIEW OF QUARTERLY UPDATES

• XTANDI AND STRATEGIC BRANDS: FY2024 KEY EXPECTED EVENTS

• PROGRESS IN FOCUS AREA APPROACH:CURRENT STATUS OF PROGRAMS IN CLINICAL TRIAL

III. Mid-term Initiatives and Latest Outlook

• OVERVIEW OF ONGOING INITIATIVES AND LATEST OUTLOOK

• MAXIMIZE POTENTIAL OF STRATEGIC BRANDS

• ADVANCE FOCUS AREA APPROACH

• SUSTAINABLE MARGIN TRANSFORMATION

• TO OVERCOME XTANDI LOE AND PURSUE FURTHER GROWTH

APPENDIX

• XTANDI AND STRATEGIC BRANDS: POTENTIAL PEAK SALES (AS OF OCT 2024)

• Q2YTD/FY2024 ACTUAL: FX RATE

• FY2024 FORECAST: FX RATE & FX SENSITIVITY

• BALANCE SHEET & CASH FLOW HIGHLIGHTS

• BALANCE OF BONDS AND BORROWINGS HIGHLIGHTS

• MAIN INTANGIBLE ASSETS (AS OF SEP 30, 2024)

• CAPITAL ALLOCATION

• CORE BASIS PERFORMANCE: CHANGES IN DEFINITIONS AND CONTEXT

• LIFECYCLE MANAGEMENT OF STRATEGIC BRANDS

• OVERVIEW OF PRIMARY FOCUS FLAGSHIP PROGRAMS (1/2)

• OVERVIEW OF PRIMARY FOCUS FLAGSHIP PROGRAMS (2/2)

• COLLABORATION WITH AVIADOBIO

• ROBUST PIPELINE OF ASTELLAS

• PROGRESS IN OVERALL PIPELINEPhase 1 Entry to Approval since the Last Financial Results Announcement

• STRATEGIC BRANDS: STATUS UPDATE

• ENZALUTAMIDE (1/2): ANDROGEN RECEPTOR INHIBITOR

• ENZALUTAMIDE (2/2): PHASE 3 STUDY DATA BY DISEASE STAGE

• ENFORTUMAB VEDOTIN (EV) (1/6): NECTIN-4 TARGETED ADCOVERALL UC PROGRAM

• ENFORTUMAB VEDOTIN (EV) (2/6): CLINICAL STUDIES

• ENFORTUMAB VEDOTIN (EV) (3/6): STUDY DATA BY DISEASE STAGE OF UC

• ENFORTUMAB VEDOTIN (EV) (4/6): STUDY DATA IN 1L MUC (EV-302)

• ENFORTUMAB VEDOTIN (EV) (5/6): STUDY DATA IN SOLID TUMORS OTHER THAN UC (EV-202)

• ENFORTUMAB VEDOTIN (EV) (6/6): FUTURE OUTLOOK

• GILTERITINIB: FLT3 INHIBITOR

• ZOLBETUXIMAB: ANTI-CLAUDIN 18.2 MONOCLONAL ANTIBODY

• FEZOLINETANT: NK3 RECEPTOR ANTAGONIST

• AVACINCAPTAD PEGOL (ACP): COMPLEMENT C5 INHIBITOR / PEGYLATED RNA APTAMER

• ON THE FOREFRONT OF HEALTHCARE CHANGE

Questions

• Questions 1

• Questions 2

• Questions 3

• Questions 4

• Questions 5

• Questions 6

• Questions 7